Abstract
We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease. Under continuous video-EEG monitoring, the clinical myoclonic status and the electrographic ictal discharges resolved within 10 minutes after the infusion was initiated. The patient tolerated the treatment well without any reported side effects. This case suggests that levetiracetam may be a safe, effective, andwell tolerated intravenous drug in patients with metabolic myoclonic status epilepticus such as Gaucher disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abend NS, Monk HM, Licht DJ, Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med 2009; 10: 505–510.
Alehan F, Ozcay F, Haberal M. The use of levetiracetam in a child with nonconvulsive status epilepticus. J Child Neurol 2008; 23: 331–333.
Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher disease. Biochem Biophys Res Commun 1965; 18: 221–225.
Frei KP, Schiffmann R. Myoclonus in Gaucher Disease. Adv Neurol 2002; 89: 41–48.
Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2: 209–212.
Glauser TA, Ayala R, Elterman RD, et al. Study group double blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66: 1654–1660.
Goraya JS, Khurana DS, Valencia I, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008; 38: 177–180.
Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001; 21: 1375–1388.
Kälviäinen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008; 49: 549–556.
Mancuso M, Galli R, Pizzanelli C, Filosto M, Siciliano G, Murri L. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243: 97–99.
Miyahara A, Saito Y, Sugai K, et al. Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus. Epilepsy Res 2009; 84: 201–209.
Nishimura R, Omos-Lau N, Ajmone-Marsan C, Barranger JA. Electroencephalographic findings in Gaucher disease. Neurology 1980; 30: 152–159.
Papacostas S, Kkolou E, Papathanasiou E. Levetiracetam in three cases of progressivemyoclonus epilepsy. PharmWorld Sci 2007; 29: 164–166.
Vigevano F. Levetiracetam in pediatrics. J Child Neurol 2005; 20: 87–93.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Fernandez-Baca Vaca, G., Lenz, T., Pestana Knight, E.M. et al. Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. Epileptic Disord. 14, 155–158 (2012). https://doi.org/10.1684/epd.2012.0501
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0501